Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Study of MPT-0118 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Refractory Solid Tumors

NCT04859777 is registered in ClinicalTrials.gov with Monopteros Therapeutics Inc. as lead sponsor.

NCT NCT04859777
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04859777 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Study of MPT-0118 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Refractory Solid Tumors
Lead sponsor
Monopteros Therapeutics Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
April 13, 2021
Completion date
March 31, 2023
Enrollment
70 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumor, metastatic cancer, refractory cancer, solid tumor, adult